|
Hematologic Malignancy Grand Rounds - FY18 The Goldilocks Zone for Immunotherapy in Acute Myeloid Leukemia |
09/15/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Optimizing the Safety of Chimeric Antigen Receptor Modified T Cells |
09/22/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Improving Outcomes in Myeloid Malignancies Using Hematopoietic Cell Transplantation |
09/29/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 The Power of Natural Killer Cells and the Future of AML Treatment |
10/06/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Breaking B Cell Tolerance to Eradicate Leukemias & Lymphomas |
10/13/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Leveraging MRD in DLBCL After CAR Therapy |
10/20/2017 - 9:00am to 10:15am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Mantle Cell Lymphoma: Prognostic Markers and Approaches to the Elderly |
10/27/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 Clinical and Molecular Characterization of Clonal Chromosomal Abnormalities Appearing in Philadelphia-Negative Metaphases of Chronic Phase CML |
11/03/2017 - 9:00am to 10:00am EDT |
|
Hematologic Malignancy Grand Rounds - FY18 |
11/10/2017 - 9:00am to 10:00am EST |
|
Hematologic Malignancy Grand Rounds - FY18 Treatment of Acute Myeloid Leukemia: Did the standard of care change in the summer of ’17? |
11/17/2017 - 9:00am to 10:00am EST |
Facebook
Twitter
LinkedIn
Forward